Gut-Brain Nexus: Mapping Multi-Modal Links to Neurodegeneration at Biobank Scale

Short Title (48 characters

Linking the Gut-Brain Axis and Neurodegeneration

Authors:

1

2 3 4

5 6

7

'	
8 9 10	Mohammad Shafieinouri ^{1*} , Samantha Hong ¹ , Artur Schuh ^{2,3} , Mary B. Makarious ^{1,4} , Rodrigo Sandon ¹ , Paul Suhwan Lee ¹ , Emily Simmonds ⁵ , Hirotaka Iwaki ^{1,4} , Gracelyn Hill ^{1,4} , Cornelis Blauwendraat ^{1,6} , Valentina Escott-Price ^{5,7} , Yue A. Oi ¹ , Alastair J. Novce ⁸ ,
11	Armando Reves-Palomares ⁹ , Hampton L. Leonard ^{1,4} , Malu Tansey ^{10,11} , Andrew
12	Singleton ^{1,6} , Mike A. Nalls ^{1,4} , Kristin S Levine ^{1,4, †} , Sara Bandres-Ciga ^{1,†*}
13	
14	Affiliations:
15	¹ Center for Alzheimer's and Related Dementias, National Institutes of Health, Bethesda,
16	MD, USA 20892.
17	² Departamento de Farmacologia, Universidade Federal do Rio Grande do Sul, Porto
18	Alegre, Brazil.
19	³ Serviço de Neurologia, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.
20	⁴ DataTecnica LLC, Washington, DC, USA 20037.
21	⁵ UK Dementia Research Institute (UK DRI) at Cardiff University, Cardiff, UK.
22	⁶ Laboratory of Neurogenetics, National Institute on Aging, Bethesda, MD, USA.
23	⁷ Division of Psychological Medicine and Clinical Neurosciences, School of Medicine,
24	Cardiff University, Cardiff, UK.
25	⁸ Centre for Preventive Neurology, Wolfson Institute of Population Health, Queen Mary
26	University of London, London, UK.
27	⁹ Department of Molecular Biology and Biochemistry, Faculty of Sciences, University of
28	Málaga, Málaga, Spain.
29	¹⁰ Department of Neuroscience, Center for Translational Research in Neurodegenerative
30	Disease, University of Florida College of Medicine, Gainesville, FL, USA.
31	¹¹ Department of Neurology, Norman Fixel Institute for Neurological Diseases, University
32	of Florida Health, Gainesville, FL, USA.
33	
34	These authors contributed equally to this work
35	* Comerce on dia a such and
36	* Corresponding authors: Mohammad Shafiainauri
3/	Monaminad Snahelhouri
38 20	Rethesde MD USA 20802
39 40	Email: mohammad shafiainouri@nih gov
40	Eman. monammad.snanemouri@mil.gov
41	Sara Bandras Ciga
42 13	Center for Alzheimer's and Related Dementias (CARD) NIA NIH
43 11	Rethesda MD USA 20802
44 45	Fmail: sara handresciga@nih gov
46	Email: buru.buru.buru.burgu @ mil.gov

47 Abstract:

Alzheimer's disease (AD) and Parkinson's disease (PD) are influenced by genetic and 48 environmental factors. Using data from UK Biobank, SAIL Biobank, and FinnGen, we 49 conducted an unbiased, population-scale study to: 1) Investigate how 155 endocrine, 50 nutritional, metabolic, and digestive system disorders are associated with AD and PD risk 51 prior to their diagnosis, considering known genetic influences; 2) Assess plasma 52 biomarkers' specificity for AD or PD in individuals with these conditions; 3) Develop a 53 multi-modal classification model integrating genetics, proteomics, and clinical data 54 55 relevant to conditions affecting the gut-brain axis. Our findings show that certain disorders elevate AD and PD risk before AD and PD diagnosis including: insulin and non-insulin 56 dependent diabetes mellitus, noninfective gastro-enteritis and colitis, functional intestinal 57 disorders, and bacterial intestinal infections, among others. Polygenic risk scores revealed 58 lower genetic predisposition to AD and PD in individuals with co-occurring disorders in 59 the study categories, underscoring the importance of regulating the gut-brain axis to 60 potentially prevent or delay the onset of neurodegenerative diseases. The proteomic 61 profile of AD/PD cases was influenced by comorbid endocrine, nutritional, metabolic, and 62 digestive systems conditions. Importantly, we developed multi-modal prediction models 63 integrating clinical, genetic, proteomic and demographic data, the combination of which 64 performs better than any single paradigm approach in disease classification. This work 65 aims to illuminate the intricate interplay between various physiological factors involved in 66 the gut-brain axis and the development of AD and PD, providing a multifactorial systemic 67 understanding that goes beyond traditional approaches. Further, we have developed an 68 interactive resource for the scientific community [https://gut-brain-nexus.streamlit.app/] 69 where researchers can investigate components of the predictive model and can investigate 70 feature effects on a sample level. 71

73 **Teaser (128 characters):**

Co-occurring disorders of the gut-brain axis combined with genetic and proteomic data can better predict neurodegenerative risk.

76 77

72

74

75

78 MAIN TEXT

79

88

80 Introduction:

Alzheimer's disease (AD) and Parkinson's disease (PD) are the two most common neurodegenerative disorders (1,2) and cumulatively affect over 400 million individuals worldwide (3,4). Though significant genetic risk factors for AD and PD have been identified, sporadic and late-onset forms are thought to be caused by a complex interplay between genetic (5,6) and environmental (7,8) factors. This interplay underscores the imperative to explore a multitude of variables across bodily systems to comprehend their contributions to the etiology of AD/PD (9,10).

Increasingly, research in neurodegeneration emphasizes the role of gut-brain axis health in neurodegeneration risk (11,12). The gut-brain axis is a complex communication network that links the gastrointestinal tract and the central nervous system. This bidirectional system, including neural pathways, hormonal signaling, and immune mechanisms,

Science Advances

facilitates constant interactions between the brain, digestive, endocrine, metabolic systems
and nutritional status. Conditions that impact the gut-brain axis include digestive system
disorders (13), endocrine pathway disorders (14,15), nutritional deficiencies (16,17), and
metabolic traits (18).

Endocrine disorders, such as thyroid hormone imbalances, have been linked to AD and PD 98 (15.19), with conditions like hypothyroidism and subclinical hyperthyroidism being 99 associated with dementia risk (20) and both hypo- and hyperthyroidism being associated 100 with increasing PD risk (15). Metabolic disorders, particularly diabetes, are also related to 101 neurodegenerative disease risk. An increased severity of diabetes is associated with a 102 higher risk of PD (21,22) and type 2 diabetes is a recognized risk factor for AD (23). 103 Consequently, antidiabetic medications are being explored as potential treatments for AD 104 and PD (24). Additionally, nutritional deficiencies such as low vitamin D levels are more 105 prevalent in AD and PD patients (25). Digestive disorders have been observed to precede 106 PD (26) or be significantly associated with an increased risk for dementia (27). These are 107 just a few examples of factors contributing to the gut-brain axis health and their influence 108 on neurodegeneration. 109

110 Understanding the connection between disorders of the gut-brain axis and 111 neurodegeneration can provide useful insights into therapeutic interventions, with major 112 implications for prevention and disease prognosis. In this study, we perform a large 113 biobank-scale characterization of the impact that disorders affecting the gut-brain axis and 114 related to endocrine, nutritional, metabolic, and digestive systems have on the risk of AD 115 and PD. Utilizing data from the UK Biobank, SAIL, and FinnGen, we conducted a 116 population-scale, unbiased assessment that aimed to: 1) Investigate the association 117 between 155 diagnoses related to endocrine, nutritional, metabolic, and digestive system 118 disorders and the risk of AD and PD, while also accounting for established genetic factors 119 known to influence the development of these conditions; 2) Evaluate the specificity of 120 plasma biomarkers associated with AD or PD when individuals have these co-occurring 121 conditions; 3) Develop a multi-modal classification model combining all these data 122 modalities; 4) Analyze the interpretability of ML models and deploy an open-access cloud 123 platform to ensure reproducibility and transparency. 124

125 126

97

- 120
- 127

Results:

A prior diagnosis of certain endocrine, nutritional, metabolic, and digestive system related disorders is associated with increased risk for Alzheimer's disease and Parkinson's disease

Cox regression models unraveled a total of 16 ICD-10 diagnoses to be significantly 132 associated with the risk of AD (table S1 and fig. S1) in the UKB after correction for 133 multiple comparisons (discovery cohort) that were also found to be significant in either 134 SAIL, FinnGen biobanks, or both (Table 1). A diagnosis of hemorrhoids and perianal 135 venous thrombosis was found to have a HR<1 for AD in all three datasets. This 136 observation could potentially be due to the fact that a hospitalized diagnosis of 137 hemorrhoids and perianal venous thrombosis could be an indication of other, more serious 138 conditions linked to a high mortality rate, thus explaining the protective observed effect 139 (28). The 15 other ICD-10 codes that were found to be significant have a HR>1, 140

suggesting that being diagnosed with these conditions increases the risk for AD; these
include amyloidosis; diseases of pulp and periapical tissues; disorders of lipoprotein
metabolism and other lipidemias; disorders of mineral metabolism; gastritis and
duodenitis; insulin-dependent, non-insulin-dependent, and unspecified diabetes mellitus;
oesophagitis; other bacterial intestinal infections; other disorders of fluid, electrolyte and
acid-base balance; other functional intestinal disorders; other noninfective gastro-enteritis
and colitis; and volume depletion.

Of note, our analyses indicate significant associations between 7 disorders and the risk for 149 PD (table S2 and fig. S2) that were replicated in either SAIL or FinnGen biobanks (Table 150 2). For PD, diverticular disease of the intestine, other diseases of the intestine, and other 151 disorders of the peritoneum have HR<1 replicated in two datasets. Similarly to AD, 152 individuals diagnosed with these conditions are not representative of the entire population 153 154 due to the severity of these conditions and differential survival rates (29–32). The other 7 ICD-10 codes that had a HR>1 include dyspepsia; insulin-dependent and non-insulin-155 dependent diabetes mellitus; and other functional intestinal disorders. 156

Additionally, we conducted a time-stratified cox regression analysis to evaluate whether the timing of diagnosis for the ICD-10 codes under study impacts HR values for AD or PD. We split the samples from UKB into three strata: 1-5 years, 5-10 years, and 10-15 years prior to AD/PD diagnosis. We then re-evaluated the HRs for AD and PD for the significant ICD-10 codes identified in the previous analysis (Table 3 and Table 4). The values and directions of the HRs in the stratified analysis show that the risk associated with each ICD-10 code is consistent across the three strata.

166Survival analysis indicates increased Alzheimer's disease and Parkinson's disease167incidence in individuals with significant diagnosis of endocrine, nutritional,168metabolic, and digestive system related disorders

Using UKB data, we conducted survival analyses to explore the probabilities of an AD 169 and PD diagnosis at a certain time interval. We generated Kaplan-Meier plots for the 170 significantly associated ICD-10 codes as depicted in fig. S3 and fig. S4, respectively. At 171 the beginning of the observation period, the survival probability starts at 1.0, indicating 172 that all individuals diagnosed with an ICD-10 code are initially free from AD and PD. 173 Over time, this probability diminishes as more individuals are diagnosed with AD or PD. 174 The curves demonstrate the impact of specific ICD-10 code diagnosis on the likelihood of 175 developing these neurodegenerative diseases. Notably, individuals with the significantly 176 associated ICD-10 code diagnoses exhibited a higher incidence of AD and PD. 177

179Genetic susceptibility for Alzheimer's disease and Parkinson's disease is higher in180isolated cases compared to those with co-occurring endocrine, nutritional, metabolic,181and digestive disorders

We compared the distribution of PRS in individuals diagnosed only with AD or PD versus those having concurrent AD/PD and any ICD-10 code diagnosis under study for samples from UKB only. Of note, some significant ICD-10 codes associated with AD included those pertaining to diabetes mellitus; other disorders of fluid, electrolyte, and acid-base balance; and obesity. Similarly, there were significant associations between diabetes mellitus, disorders of the peritoneum, and vitamin B group deficiencies, and PD. A comprehensive summary of these results is shown in fig. S5 and fig. S6.

189

178

148

157

190	For all significant t-tests, a lower average PRS was observed in individuals with co-
191	occurring AD and another condition compared to individuals with only AD. For instance,
192	in AD patients with a non-insulin-dependent diabetes mellitus diagnosis, our analysis
193	revealed lower average PRS scores compared to individuals with only AD, either
194	including or excluding APOE (t-test = -4.26 , P = $2.3e-5$ and t-test = -2.88 , P = $4.01e-3$,
195	respectively). Similar trends were observed in individuals with AD and other bacterial
196	intestinal infections (including APOE t-test = -2.31, P = 2.24e-02; excluding APOE t-test
197	= -2.26 , P = $2.54e-02$), other disorders of pancreatic internal secretion (including APOE t-
198	test = -2.17 , P = $3.12e-02$), oesophagitis (including APOE t-test = -3.08 , P = $2.33e-02$;
199	excluding APOE t-test = -2.39 , P = $1.78e-02$), as well as gastritis and duodenitis
200	(including APOE t-test = -2.83 , P = $4.76e-03$).
201	
202	Of note, lower average PRS was observed for all significant t-tests in individuals with co-
203	occurring PD and another condition compared to individuals with only PD. For instance,
204	PD patients with other disorders of the peritoneum had a lower average PRS score than
205	those with only PD (t-test = -3.00 , P = $3.70e-03$). Additionally, individuals with PD and
206	other functional intestinal disorders (t-test = -2.08 , P = $3.80e-02$), insulin-dependent
207	diabetes (t-test = -2.55 , P = $1.29e-02$), non-insulin dependent diabetes (t-test = -3.68 , P =
208	2.52e-4), or a deficiency of other B group vitamins (t-test = -2.54 , P = $1.23e-02$) also had
209	lower average PRS scores than individuals with only PD.
210	
211	This result must be interpreted with caution, as there is potential for collider bias in our
212	analysis. By selecting individuals with AD/PD, we are conditioning on these disorders,
213	which are influenced by both the PRS for AD/PD and other risk factors, such as co-
214	occurring endocrine, nutritional, metabolic, and digestive disorders. This conditioning can
215	induce a spurious association between the PRS for AD/PD and these other risk factors,
216	leading to the appearance of a lower average PRS in the group with AD/PD and co-
217	occurring disorders. Essentially, this bias might make it seem as though lower genetic risk
218	is linked to AD/PD in the presence of ICD-10 diagnoses, when in fact the relationship

219 220

221

222

223

229

230

231

232

The interplay between AD and PD cumulative known genetic effects and the risk for endocrine, nutritional, metabolic, and digestive systems disorders did not display any synergistic impact

We did not identify significant synergistic interaction terms at a nominal P<0.05 and exhibiting an OR>1 in either AD (see table S3 and table S4) or PD (see table S5). This suggests that the combined occurrence of endocrine, nutritional, metabolic, or digestive system related disorders does not lead to a synergic effect on AD/PD risk that surpasses the sum of their individual impacts.

may be driven by the complex interplay of risk factors.

The proteomic profile of individuals diagnosed with Alzheimer's disease and Parkinson's disease is influenced by comorbid endocrine, nutritional, metabolic, and digestive systems conditions

Our analysis showed 22 proteomic biomarkers with notable differences in AD cases versus controls, alongside 156 proteins exhibiting significant distinctions in PD cases compared to controls after controlling for multiple comparisons (table S6 and table S7, respectively). We delved deeper into the levels of proteomic biomarkers, applying a t-test to juxtapose average levels between standalone cases of AD/PD and cases co-occurring with specific ICD-10 codes. After implementing FDR corrections, we found significant differences in proteomic biomarker levels in individuals with only AD/PD compared to

individuals with AD/PD and co-occurring ICD-10 conditions. Specifically, we observed
that 37 biomarkers displayed increased levels in AD cases with co-occurring ICD-10
diagnosis compared to isolated AD cases (Table 5), while a total of five biomarkers
demonstrated significant elevated levels in PD cases with accompanying conditions
compared to standalone PD cases (Table 6). These findings hint at distinct associations
between specific biomarkers and AD/PD, while others may be influenced by concurrent
comorbidities.

Multi omics integration models based on clinical, genetic, and proteomic data improve accuracy to predict Alzheimer's disease and Parkinson's disease risk versus a single paradigm

In our analysis, the combination of genetic, clinical, proteomic (controlling for multiple 251 comparisons using Bonferroni correction), and demographic factors (including age at 252 253 recruitment and gender) exhibited superior predictive performance for AD risk when compared to the individual data sets, with a test AUC of 0.9 [95% CI 0.88-0.92] and test 254 balanced accuracy (BA) of 0.83 [0.80-0.86]. Curiously, the model combining genetic, 255 proteomic, and demographic features (i.e. no clinical information) had a very similar test 256 AUC of 0.89 [0.87-0.91] and a test BA of 0.82 [0.78-0.86], suggesting that the risk 257 information captured by clinical features may be encompassed within the information 258 provided by genetic, proteomic, and demographic features. The best classifier using only 259 one data attribute was the model that used only proteomic data for prediction with a test 260AUC of 0.87 [0.85-0.89] and test BA of 0.79 [0.76-0.82]. The performance of each 261 predictive model is shown in fig. 1 and the metrics are listed in table S8. 262

For PD, the integration of genetic, proteomic and demographic factors showcased 264heightened predictive efficacy with a test AUC of 0.78 [0.74-0.82] and test BA of 0.70 265 [0.68-0.72]. For PD, addition of the clinical data did not improve the AUC and test BA of 266 the model. Clinical features do not contain any useful information and predicting solely on 267 clinical features perform no better than a random classifier, with a test AUC of 0.52 [0.49-268 0.55]. The best classifier using only one data attribute was the model that used 269 demographics data (Age at recruitment, Sex, and Townsend_deprivation_index), with a 270 test AUC of 0.77 [0.74-0.80] and a test BA of 0.72 [0.68-.76]. The performance of each 271 model for PD is shown in fig. 2 and table S9. 272

SHAP values provide an in-depth analysis of machine learning classifiers by highlighting 274 the top discriminating features of AD/PD compared to healthy controls. The biological 275 plausibility of the models is supported by feature importance plots, which emphasize 276 known risk factors for AD and PD, such as age and PRS. Among the proteomic features, 277 neurofilament light polypeptide (NLF) emerges as a significant factor for both AD and 278 PD, suggesting its potential as a biomarker for multiple forms of neurodegeneration. In 279 AD, other top features include glial fibrillary acidic protein (GFAP) and growth 280 differentiation factor (GDF) from proteomics data. From clinical features, only gastritis 281 and duodenitis appear among top features (fig. 3A). Proteomic factors, including 282 Adhesion G-protein coupled receptor G2 and Integrin alpha-M and Interleukin receptor, 283 help distinguish PD from controls (fig. 3B). The interactive website (https://gut-brain-284 nexus.streamlit.app/) was developed as an open-access and cloud-based platform for 285 researchers to investigate the top features of the machine learning models developed and 286 how these may influence the AD/PD risk scores. Finally, the screenshots of our cloud-287 based interpretability analysis and multimodal prediction tool are shown in fig. S7-S10. 288

289

247

248

249

250

263

- 290
- 291

302

318

327

292 **Discussion:**

With the increasing prevalence of AD (33) and PD (34), it is imperative to enhance our 293 understanding of the determinants that increase the risk for these common 294 neurodegenerative diseases and most importantly, develop improved prediction models for 295 early detection. Here, we have undertaken the most extensive biobank-scale omics study 296 to date to assess the influence of main biological system disorders implicated in the gut-297 brain axis (including endocrine, nutritional, metabolic, and digestive-related conditions) 298 preceding the diagnosis of AD and PD. The culmination of which is a multi-modal 299 classification model that combines clinical, genetics, and proteomics data enhancing the 300 prediction accuracy of AD and PD. 301

In a large-scale and data driven manner, we demonstrate that certain endocrine, 303 nutritional, metabolic, and digestive system related disorders are significantly associated 304 with an increased risk of AD and/or PD prior to diagnosis. Of note, individuals with other 305 non-infective gastroenteritis and colitis; oesophagitis; gastritis and duodenitis; disorders of 306 fluid, electrolyte, and acid-base balance; pancreatic internal secretion disorders; and other 307 functional intestinal disorders showed a higher likelihood of developing AD later in life. 308 Recent literature has suggested the amplification of AD risk from disorders affecting the 309 gut-brain axis, such as gastritis (35). Our results corroborate these findings and reveal 310 additional, novel potential disorders of interest for further study, with replication across 311 multiple datasets. In regards to PD, significant diagnoses associated with increased PD 312 risk include other functional intestinal disorders, disorders of pancreatic internal secretion, 313 and deficiency of other B group vitamins. The correlation between the deficiency of other 314 B group vitamins and PD expands upon previous studies that have looked at other vitamin 315 deficiencies, such as vitamin D (25), and warrants more research on the impact of 316 nutritional deficiencies on neurodegenerative diseases. 317

Our study robustly demonstrates that the probability of developing AD/PD increases with 319 320 certain co-occurring endocrine, metabolic, digestive, or nutritional conditions, corroborating the hypothesis that a diagnosis affecting the gut-brain axis elevates the risk 321 of AD/PD. We also show that risk of neurodegeneration persists up to 15 years before 322 AD/PD onset with a co-occurring diagnosis of an endocrine, metabolic, digestive or 323 324 nutritional disorder or trait. For example, having a diagnosis of other functional intestinal disorders results in an increased HR for both AD and PD in the periods 1-5, 5-10, and 10-325 15 years prior to AD/PD diagnosis. 326

In an effort to investigate genetic distinctions and potential etiological subtypes of AD and 328 PD, we compared polygenic risk for AD and PD in individuals diagnosed only with AD or 329 PD and individuals with AD or PD co-occurring with other endocrine, nutritional, 330 metabolic, and digestive-related disorders. Of note, our study confirmed that individuals 331 diagnosed with any type of diabetes mellitus in addition to AD or PD are shown to have a 332 significant different PRS than individuals with AD or PD alone, in concordance with 333 previous studies showing that diabetes is a risk factor for both AD and PD (36-38). For 334 both AD and PD, comorbidity with any of the significant disorders affecting the gut-brain 335 axis showed lower average PRS scores compared to those with only AD or PD. Our 336 findings suggest that systemic health risk factors can more prominently account for one's 337

disease risk in the absence of other genetic risk factors in patients with AD or PD, 338 highlighting the importance of considering both genetic as well as other health factors in 339 assessing the overall risk of developing AD and PD. Using diabetes as a positive control 340 in our study, we found that individuals diagnosed with AD along with another disorder 341 affecting the gut-brain axis, such as other bacterial intestinal infections and other 342 functional intestinal disorders, result in a significantly lower average PRS score compared 343 to individuals with only AD. This suggests that severe digestive conditions such as 344 345 infections affecting the gut microbiome, independent of genetic risk, could increase the risk for AD as previously described (39). For PD, there existed a significant difference in 346 PRS in individuals without vs. with other functional intestinal disorders and other 347 disorders of the peritoneum, in concordance with previous studies suggesting an influence 348 of disorders involving the gut-brain axis on PD (40). 349 350

In addition, our analysis revealed that the relationship between the genetic risk for AD/PD 351 and many disorders of the endocrine, nutritional, metabolic and digestive systems resulted 352 in a combined impact not significantly greater than the sum of their individual effects. 353 These interactions are not synergistic, confirming the notion that known genetic risk 354 factors included in the models under study for both AD and PD are independent from 355 gastrointestinal and metabolic disorders, which highlights the importance of 356 environmental factors in the development of both AD and PD. While both genetic and 357 systemic health disorders independently influence the risk of AD and PD, many disorders 358 may not interact in a way that significantly amplifies this risk when combined. 359

Through our exploration of proteomics and AD/PD risk, we identified several promising 361 candidates for AD/PD diagnosis. For instance, we found that for AD, the proteomic 362 biomarker with the largest impact on disease was glial fibrillary acidic protein (GFAP), 363 supporting previous literature findings that GFAP can serve as an indicator of AD 364 pathology (41). However, the levels of GFAP were significantly decreased in samples 365 with AD and a co-occurring ICD-10 code for gastritis and duodenitis or non-insulin 366 dependent diabetes mellitus. For PD, in concordance with previous studies, we identified 367 peroxiredoxin 1 (PRDX1) as a potential biomarker for disease (42). Again, the levels of 368 PRDX1 were significantly decreased in PD cases and a coinciding ICD-10 code for 369 insulin-dependent diabetes mellitus. These differences in biomarker levels between 370 samples solely with AD/PD vs. samples with additional diagnoses highlight the influence 371 of comorbidities on disease manifestation. Although longitudinal research would need to 372 be conducted, our findings suggest that these biomarkers could serve as valuable 373 diagnostic or prognostic tools for AD and PD, potentially enhancing early detection and 374 disease management. 375

The inclusion of multiple features, integrating clinical data on digestive, endocrine, 377 nutritional and metabolic disorders, genetic risk scores, and proteomic data in our 378 prediction model, demonstrated superior performance in predicting both AD and PD 379 compared to single-variable paradigms. Co-occurring diagnosis for conditions influencing 380 the gut-brain axis do not seem to influence the predictability of neither AD nor PD as 381 much as the other variables (demographic factors, biomarkers, and genetic status), but the 382 fact that for both AD and PD the combination of data (clinical, genetic, proteomic, and 383 demographic) produces a higher AUC for the ROC curve compared to single modalities 384 underscores the value in including multiple facets of data in predictive models. Overall, 385 these results from our models reveal the promising predictive capabilities of our 386 constructed multi-modal classification models in identifying individuals at risk for 387

360

AD/PD. The study suggests that the selected proteomic biomarkers, when combined with 388 genetic and other demographic and clinical variables, serve as robust predictors. These 389 predictors have the potential to significantly enhance prediction diagnostic accuracy for 390 AD/PD. In addition, neurofilament light polypeptide proteomic feature stands out as a key 391 factor for both AD and PD, indicating its potential as a biomarker for various forms of 392 neurodegeneration. Our approach highlights the potential clinical utility of multi-omics in 393 enhancing diagnostic accuracy, and further emphasizes the importance of considering 394 395 other bodily systems when predicting the risk underlying neurodegenerative diseases.

Transparency and reproducibility are critical aspects of science. This becomes even more 397 important for machine learning models due to their dependency on data and the black-box 398 nature of these models. To facilitate this, we made two contributions: (1) Model 399 interpretability analysis, using SHAP values to identify the top features, corresponding to 400 each modality, that can be validated against existing biological findings; (2) Development 401 of an open-access, cloud-based platform for researchers to explore the model developed in 402 this study and investigate how different factors may influence the classification (or, in 403 some cases, misclassification) of a particular sample. Additionally, we incorporated a 404 model perturbation analysis feature on our website, allowing researchers to manually 405 adjust features and observe the resulting changes. These efforts enhance transparency and 406 move the research community away from black-box predictors through interpretable 407 modeling. 408

Some overall limitations of our work include the use of solely ICD-10 codes for diagnosis, 410 and not other additional assays, which may overlook undiagnosed cases, leading to a 411 potential underestimation of the true impact of these disorders on AD/PD risk. Across 412 datasets, the available diagnosis codes also differ causing further limitations in 413 comparison and validation. Because individuals with AD often present with different 414 cognitive, behavioral, and pathological features, diagnosis of AD is often difficult and 415 inconsistent (43). Though we use the ICD-10 code to filter for AD in this study, it is 416 possible for AD to be interchanged with dementia as diagnosing AD is difficult. The 417 sample makeup across data sources can also be different. Since the UKB participants are 418 volunteers who may have agreed to participate before reaching old age, the incidence of 419 AD/PD may be different compared to the SAIL and FinnGen datasets. The cross-sectional 420 nature of the data used to study biomarker associations may limit any causal inference. 421 The SAIL and FinnGen datasets do not include proteomic data, preventing us from further 422 validating our modeling efforts. The focus on samples of European ancestry constrains the 423 generalizability of our findings to other populations from other genetic backgrounds. 424 Future work needs to be done across different ancestral backgrounds to be globally 425 representative. 426

Our study delves into the intricate interactions between clinical, genetic and proteomic 428 data, culminating in the construction of a comprehensive multi-modal classification 429 model. This pioneering endeavor aims to shed light on the nuanced interplay between 430 various physiological factors playing a role on the gut-brain axis and the development of 431 AD and PD, offering a multifactorial systemic understanding that transcends traditional 432 approaches. Our integrated approach serves as a proof of concept, aligning with the 433 expanding body of evidence that underscores the intricate etiological foundations of 134 neurodegenerative diseases and holds promise for refining risk prediction models and 435 devising targeted preventive strategies. Further, we have developed an interactive resource 436 for the scientific community [https://gut-brain-nexus.streamlit.app/]. This, in turn, propels 437

396

409

our endeavors in elucidating clinical interventions aimed at addressing these debilitating conditions.

139 140

438

- 1/1
- 441
- 442
- 443
- 144 145

450

474 475

176

446 Materials and Methods:

This study utilizes data from three biobanks: the UK Biobank (UKB), FinnGen, and the
Secure Anonymized Information Linkage (SAIL) (See fig. 4 for an workflow rationale of
this study).

451 UK Biobank

The UKB data, accessed via DNAnexus under application number 33601, includes 452 electronic health records of approximately 502,367 individuals, single nucleotide 453 polymorphism (SNP) data of 487,279 individuals, and proteomic (Olink) data of 52,705 454 individuals (https://ukbiobank.dnanexus.com) (accessed on May 2023). The control group 455 for the UKB dataset consisted of a subset of 352,610 individuals who have not been 456 diagnosed with any neurodegenerative disease condition (table S10) and have no family 457 history AD and PD diagnosis. For our approach, related individuals were filtered out from 458 further analyses based on a kinship coefficient greater than 0.0884, and only individuals of 459 European descent were selected for this study, based on field ID 22006, who self-460 identified as 'White British' and confirmed through principal component (PC) analysis of 461 the genotyping data to avoid potential confounding effects. We lacked a sufficient number 462 of individuals with non-European ancestry to conduct a meaningful assessment. Our final 463 dataset included 409,520 individuals of European ancestry. Endocrine, nutritional, 464 metabolic, and digestive disorders, as well as AD and PD diagnosis, were derived from 465 ICD-10 (International Classification of Diseases, 10th Revision) codes. The AD cohort 466 was obtained from the G30 and F00 ICD-10 codes in the UKB, and the PD cohort was 467 obtained from the G20 ICD-10 code. We excluded any individuals who had received an 468 ICD-10 diagnosis for endocrine, nutritional, metabolic, and digestive disorders before 469 January 1st, 1999, and right-censored any individuals who received an ICD-10 diagnosis 470 after being diagnosed with AD or PD. Furthermore, any ICD-10 code with fewer than 5 471 472 cases was excluded from the analysis. Demographic characteristics are shown in table S11. 473

SAIL Databank

The Secure Anonymised Information Linkage (SAIL) databank is a virtual platform 177 478 providing anonymized medical data of the population in Wales (44). Diagnoses in SAIL are sourced from the Patient Episode Database for Wales (PEDW), records from clinicians 179 and hospital staff, the Welsh Longitudinal General Practitioner dataset (WLGP), records 480 from primary care physicians of diagnoses, treatments, symptoms, and referrals. 481 Demographic information such as sex, age, address, and death were obtained from the 482 Welsh Demographic Services Database (WDSD) and WLGP. Individuals with missing 483 age or sex data and those without a Welsh address were excluded from further analysis. 184 485

486 Diagnoses were identified in the PEDW using ICD-10 codes and in the WLGP using NHS read codes (CVT2,3). Neurodegenerative disorders from the outpatient data (OPDW) were 487 excluded due to their minimal representation of dementia cases (only 0.1%) and the 488 absence of reliable diagnosis dates. Similarly, dementia diagnoses from death records 189 (ADDES) were not included due to inaccurate diagnosis dates. This study covered the 490 period from January 1, 1999, to December 31, 2018. For inclusion, individuals were 491 required to have been alive at the start of 1999 and to have been at least 45 years old on 492 493 January 1, 1999.

FinnGen Biobank

194

495

514

515

525

526

The FinnGen study is a large-scale genomics initiative that has analyzed over 500,000 Finnish biobank samples and correlated genetic variation with health data to understand disease mechanisms and predispositions. The project is a collaboration between research organisations and biobanks within Finland and international industry partners (45). FinnGen provides survival analyses across numerous clinical endpoints. The hazard ratios are adjusted for sex and year of birth. FinnGen bases the calculation of these hazard ratios on a wide array of clinical endpoints defined through data from nationwide registries,

- 503 including, but not limited to, Statistics Finland
- [https://finngen.gitbook.io/documentation/methods/endpoints]. We downloaded the hazard
 ratios for AD/PD from FinnGen's Risteys R10 platform for AD using the G6_AD_WIDE
 category matching more closely the UKB grouping than G6_AD
- 507 [https://r10.risteys.finngen.fi/endpoints/G6_AD_WIDE] and for PD
- 508 [https://r10.risteys.finngen.fi/endpoints/G6_PARKINSON] to explore the putative impact 509 of endocrine, digestive, metabolic, and nutritional disorders on the risk of of AD/PD prior 510 to diagnosis. It is important to note that not all ICD-10 codes used in our discovery phase 511 in the UKB are represented in the FinnGen dataset. This discrepancy is perhaps due to the 512 differences in health registries and data collection methodologies between the UKB and 513 FinnGen biobanks.

Polygenic Risk Score Analyses

Risk allele loci and beta values from GWAS summary statistics, specifically 23 risk 516 predictors linked to AD risk from Kunkle 2019 and 90 risk predictors associated with PD 517 from Nalls 2019, were used to estimate PRS for AD and PD respectively (46,47). Each 518 risk allele was assigned a weight based on the magnitude of its effect in the published 519 studies, giving greater emphasis to alleles with higher risk estimates. Genetic variants 520 were extracted for each individual from the UKB imputed data using the 'bgenix' package 521 (48). The extracted variants were then converted to binary formats and used to compute 522 the PRS score for each individual using PLINK 2.0 (49). Estimated profiles were then 523 normalized to Z-scores based on a control reference. 524

Cox Proportional Hazard Model

A Cox proportional hazards model was used to calculate the hazard ratio between risk for 527 incident AD and PD and endocrine, nutritional, metabolic, and digestive system disorders. 528 The disorders under study are represented as 155 ICD-10 codes (table S12). In this model, 529 January 1st, 1999 was used as the cutoff date for the diagnosis of these conditions. 530 Consequently, any individual diagnosed with these traits before January 1st, 1999 was 531 excluded from the analysis. Logistic regressions and Cox proportional hazards models 532 were adjusted for age, sex, the Townsend deprivation index, and 5 PCs to account for 533 population stratification (precomputed in UKB only). Additionally, we conducted Time-534 Stratified Cox Regression Analysis, for which cohorts were divided into three strata based 535

536on ICD-10 codes: 1-5 years, 5-10 years, and 10-15 years prior to NDD diagnosis. ICD-10537diagnoses within the specified time periods were retained, while any ICD-10 codes outside538of these time frames were converted to NaN.

540 **Polygenic Risk Score distribution for Alzheimer's disease and Parkinson's disease**

A t-test was used to quantify the differences in the distribution of genetic alleles for AD or 541 PD between individuals diagnosed only with AD or PD and individuals with an additional, 542 543 significant ICD-10 diagnosis. This approach measures how much the cumulative effect of these alleles varies between the two groups. Additionally, it unveils the genetic risk 544 profiles for AD and PD in both groups. By calculating and comparing PRSs based on 545 alleles associated with AD or PD, the analysis evaluates how the genetic predisposition to 546 AD or PD is increased or decreased among those individuals diagnosed with one of the 547 ICD-10 codes in addition to AD or PD. This comparison aids in understanding whether 548 549 genetic risk for AD or PD is similar or distinct in the compared subgroups of study.

Statistical Analysis accounting for the Impact of APOE, LRRK2, and GBA1 risk variants

PRS analyses were adjusted for major genetic risk factors associated with AD and PD to 553 determine if observed similarities or differences between AD/PD and the assessed ICD-10 554 codes could be attributed to pleiotropic effects. For AD, individuals homozygous for the 555 'C' allele at both APOE rs429358 and rs7412 were identified as having two copies of the 556 APOE-ɛ4 allele, coded as '2', and one copy of the APOE-ɛ4 allele coded as '1' in our 557 regression analysis to indicate a higher genetic risk. All other configurations were coded 558 as '0'. For PD, we examined LRRK2 at rs76904798, where homozygous 'C' alleles were 559 coded as '0', and heterozygous and homozygous for 'T' alleles as '1'. Similarly, at 560 rs34637584 (LRRK2 G2019S), we applied '0' for homozygous 'G' alleles, and '1' for 561 heterozygous and homozygous 'A' alleles. For GBA1, at rs35749011 (proxy for GBA1 562 E326K), '0' was assigned to homozygous 'G' alleles, '1' to heterozygous and homozygous 563 'A' alleles, and at rs76763715 (GBA1 N370S), '0' for homozygous 'T', and '1' for 564 heterozygous and homozygous 'C' alleles. 565

Interaction model for genetic risk across endocrine, metabolic, digestive system disorders and nutritional status

We aimed to understand how the interplay between genetics underlying AD and PD risk and a clinical diagnosis for any investigated ICD-10 code could eventually influence an AD or PD diagnosis. A Generalized Linear Model (GLM) was used to account for more complex relationships, where the impact of genetic risk for AD or PD (as measured by PRS) might interact differently across the diagnoses under study represented by ICD-10 codes. The interaction term used in this model was: Z-score * ICD-10 terms adjusted by sex, age and Townsend deprivation index.

Proteomic Biomarker Data Analyses

We aimed to explore differences in the levels of proteomic biomarkers associated with AD 578 or PD between individuals with and without co-occurring ICD-10 code diagnoses related 579 to endocrine, nutritional, metabolic, and digestive system disorders among UKB 580 participants. For this purpose, we utilized data from the Pharma Proteome Project, which 581 provides thousands of plasma protein biomarkers in blood samples 582 (https://olink.com/news/uk-biobank-pharma-proteomics-project/). In a cross-sectional 583 analysis, we focused on baseline (Instance 0) proteomics data, as it includes 584 measurements for the largest number of individuals, encompassing data for 52,705 585

539

550

551

552

566

567

568

576

individuals (at the time of data access) and a total of 1,463 proteins (table S13). These
 biomarkers span across cardiometabolics, inflammation, neurology, and oncology
 markers.

We applied GLM to analyze 1,463 available biomarkers on AD and PD risk. The 590 regressions were adjusted for age at recruitment, Townsend deprivation index, sex, and 5 591 PCs. Subsequently, we selected False Discovery Rate (FDR)-corrected significant 592 593 proteomic biomarkers from the GLM results. Additionally, we compared the average levels of proteomic biomarkers in isolated cases of AD/PD with cases of AD/PD co-594 occurring with selected ICD-10 codes (found to be significantly associated with AD or PD 595 risk before AD/PD diagnosis). We selected FDR-corrected significant proteomic 596 biomarkers with an OR greater than 1 and applied a t-test to compare their average levels 597 in the isolated cases of AD or PD and cases co-occurring with specific ICD-10 codes. 598

Multi-modal classification model for clinical, genetics and proteomics on Alzheimer's disease and Parkinson's disease risk

To evaluate the role of endocrine, metabolic, digestive and nutritional status-related 502 diagnoses in predicting AD or PD status, we developed a multi-modal classification model 503 on a subset of the UK Biobank dataset. This subset included individuals with variables 504 encompassing clinical diagnosis for endocrine, metabolic, digestive and nutritional status; 505 biomarkers; demographic factors (age at recruitment, sex, and Townsend deprivation 506 index); derived variables (Z score for the PRS); PCs; and APOE status for AD, or 507 LRRK2/GBA1 status for the PD model. The clinical diagnoses used in these models 508 include the ICD-10 codes found to have significant HRs in UKB. We employed a machine 509 learning approach to compare the predictive performance of various feature sets on 510 AD/PD outcomes. These included genetics, clinical, proteomic, demographics (including 511 sex, age at recruitment), and combinations thereof. Each dataset was independently 512 analyzed using a Gradient Boosting Classifier, an ensemble learning method for 513 classification tasks [https://scikit-514

learn.org/stable/modules/generated/sklearn.ensemble.GradientBoostingClassifier.html]. 515 We conducted hyperparameter tuning through GridSearchCV, optimizing for the number 516 of estimators, learning rate, and maximum depth. For AD classification, the grid search 517 adjusts XGBClassifier parameters including n estimators (2, 3, 5, 10, 15), learning rate 518 (0.001, 0.01, 0.1), and max depth (3, 4, 5). For PD, it adjusts n estimators (300, 500), 519 learning_rate (0.005, 0.01), and max_depth (1, 2, 3). Both models use nested cross-520 validation, optimizing based on Receiver Operating Characteristic Area Under the Curve 521 (ROC AUC). We used 5 folds for both inner and outer cross-validation. Feature selection 522 was performed using the Least Absolute Shrinkage and Selection Operator (LASSO) as a 523 part of the hyperparameter tuning procedure. The dataset was downsampled to have an 524 equal number of cases and controls, and then scaled using StandardScaler to ensure 525 uniformity and prevent bias due to variance in measurement scales before classification 526 training. Model performance was evaluated based on ROC AUC and balanced accuracy 527 (BA) scores. The 95% confidence intervals (CI) were calculated based on performance 528 metrics obtained from a 5-fold cross-validation. We employed the Shapley Additive 529 Explanations (SHAP) approach to assess the impact of each feature on the machine 530 learning model predictions (50). SHAP values are derived from game theory and 531 approximate a feature's effect on the model. SHAP enhances understanding by creating 532 accurate explanations for each observation. The SHAP package was used to calculate and 533 visualize these Shapley values seen in the figures in the manuscript and the interactive 534

589

599

500

website. A surrogate LightGBM regression model (https://lightgbm.readthedocs.io/) was 535 trained on the risk estimates to calculate SHAP values. 536

- 537
- 538
- 539

542

543

553

554 555

556

557

559

564 565

References: 540

- 1. Lane CA, Hardy J, Schott JM. Alzheimer's disease. Eur J Neurol. 2018 Jan;25(1):59–70. 541
 - 2. Tolosa E, Garrido A, Scholz SW, Poewe W. Challenges in the diagnosis of Parkinson's disease. Lancet Neurol. 2021 May;20(5):385-97.
- 3. Gustavsson A, Norton N, Fast T, Frölich L, Georges J, Holzapfel D, et al. Global 544 estimates on the number of persons across the Alzheimer's disease continuum. Alzheimers 545 Dement. 2023 Feb;19(2):658-70. 546
- 4. Ou Z, Pan J, Tang S, Duan D, Yu D, Nong H, et al. Global Trends in the Incidence, 547 Prevalence, and Years Lived With Disability of Parkinson's Disease in 204 548 Countries/Territories From 1990 to 2019. Front Public Health. 2021 Dec 7:9:776847. 549
- 5. Rabinovici GD. Late-onset Alzheimer Disease. Continuum . 2019 Feb;25(1):14–33. 550
- 6. Simon DK, Tanner CM, Brundin P. Parkinson Disease Epidemiology, Pathology, 551 Genetics, and Pathophysiology. Clin Geriatr Med. 2020 Feb;36(1):1–12. 552
 - 7. Bellou V, Belbasis L, Tzoulaki I, Evangelou E, Ioannidis JPA. Environmental risk factors and Parkinson's disease: An umbrella review of meta-analyses. Parkinsonism Relat Disord. 2016 Feb:23:1–9.
 - 8. Migliore L, Coppedè F. Gene-environment interactions in Alzheimer disease: the emerging role of epigenetics. Nat Rev Neurol. 2022 Nov;18(11):643-60.
- 9. Santiago JA, Potashkin JA. The Impact of Disease Comorbidities in Alzheimer's Disease. 558 Front Aging Neurosci. 2021 Feb 12;13:631770.
- 10. Santiago JA, Bottero V, Potashkin JA. Biological and Clinical Implications of 560 Comorbidities in Parkinson's Disease. Front Aging Neurosci. 2017 Dec 4;9:394. 561
- 11. Tan AH, Lim SY, Lang AE. The microbiome-gut-brain axis in Parkinson disease from 562 basic research to the clinic. Nat Rev Neurol. 2022 Aug;18(8):476–95. 563
 - 12. Kowalski K, Mulak A, Brain-Gut-Microbiota Axis in Alzheimer's Disease, J Neurogastroenterol Motil. 2019 Jan 31;25(1):48–60.
- 13. Kang J, Lee M, Park M, Lee J, Lee S, Park J, et al. Slow gut transit increases the risk of 566 Alzheimer's disease: An integrated study of the bi-national cohort in South Korea and 567 Japan and Alzheimer's disease model mice. J Advert Res [Internet]. 2023 Dec 13; 568 569 Available from: http://dx.doi.org/10.1016/j.jare.2023.12.010
- 14. Moon JH. Endocrine Risk Factors for Cognitive Impairment. Endocrinol Metab (Seoul). 570 2016 Jun;31(2):185-92. 571
- 15. Charoenngam N, Rittiphairoj T, Ponvilawan B, Prasongdee K. Thyroid Dysfunction and 572 Risk of Parkinson's Disease: A Systematic Review and Meta-Analysis. Front Endocrinol . 573 2022 May 4;13:863281. 574
- 575 16. Chai B, Gao F, Wu R, Dong T, Gu C, Lin Q, et al. Vitamin D deficiency as a risk factor for dementia and Alzheimer's disease: an updated meta-analysis. BMC Neurol. 2019 Nov 576 13;19(1):284. 577
- 17. Pignolo A, Mastrilli S, Davì C, Arnao V, Aridon P, Dos Santos Mendes FA, et al. Vitamin 578 D and Parkinson's Disease. Nutrients [Internet]. 2022 Mar 14;14(6). Available from: 579 http://dx.doi.org/10.3390/nu14061220 580

- 18. Colca JR, Finck BN. Metabolic Mechanisms Connecting Alzheimer's and Parkinson's
 Diseases: Potential Avenues for Novel Therapeutic Approaches. Front Mol Biosci. 2022
 Jun 16;9:929328.
- 19. Kim JH, Lee HS, Kim YH, Kwon MJ, Kim JH, Min CY, et al. The Association Between
 Thyroid Diseases and Alzheimer's Disease in a National Health Screening Cohort in
 Korea. Front Endocrinol . 2022 Mar 7;13:815063.
- 20. Ma LY, Zhao B, Ou YN, Zhang DD, Li QY, Tan L. Association of thyroid disease with
 risks of dementia and cognitive impairment: A meta-analysis and systematic review. Front
 Aging Neurosci. 2023 Mar 13;15:1137584.
- 590 21. Han K, Kim B, Lee SH, Kim MK. A nationwide cohort study on diabetes severity and risk
 591 of Parkinson disease. NPJ Parkinsons Dis. 2023 Jan 27;9(1):11.
- 22. Chohan H, Senkevich K, Patel RK, Bestwick JP, Jacobs BM, Bandres Ciga S, et al. Type
 2 Diabetes as a Determinant of Parkinson's Disease Risk and Progression. Mov Disord.
 2021 Jun;36(6):1420–9.
- 23. Athanasaki A, Melanis K, Tsantzali I, Stefanou MI, Ntymenou S, Paraskevas SG, et al.
 Type 2 Diabetes Mellitus as a Risk Factor for Alzheimer's Disease: Review and MetaAnalysis. Biomedicines [Internet]. 2022 Mar 27;10(4). Available from:
 http://dx.doi.org/10.3390/biomedicines10040778
- 24. Nowell J, Blunt E, Gupta D, Edison P. Antidiabetic agents as a novel treatment for
 Alzheimer's and Parkinson's disease. Ageing Res Rev. 2023 Aug;89:101979.
 - 25. Zhao Y, Sun Y, Ji HF, Shen L. Vitamin D levels in Alzheimer's and Parkinson's diseases: a meta-analysis. Nutrition. 2013 Jun;29(6):828–32.
- 26. Konings B, Villatoro L, Van den Eynde J, Barahona G, Burns R, McKnight M, et al.
 Gastrointestinal syndromes preceding a diagnosis of Parkinson's disease: testing Braak's
 hypothesis using a nationwide database for comparison with Alzheimer's disease and
 cerebrovascular diseases. Gut. 2023 Nov;72(11):2103–11.
- Yuan S, Dan L, Zhang Y, Wu J, Zhao J, Kivipelto M, et al. Digestive System Diseases,
 Genetic Risk, and Incident Dementia: A Prospective Cohort Study. Am J Prev Med. 2024
 Mar;66(3):516–25.
- 28. Delcò F, Sonnenberg A. Associations between hemorrhoids and other diagnoses. Dis
 Colon Rectum. 1998 Dec;41(12):1534–41; discussion 1541–2.
- 29. Cameron R, Walker MM, Thuresson M, Roelstraete B, Sköldberg F, Olén O, et al.
 Mortality risk increased in colonic diverticular disease: a nationwide cohort study. Ann
 Epidemiol. 2022 Dec;76:39–49.
- 30. Lucey BC, Varghese JC, Soto JA. Spontaneous hemoperitoneum: causes and significance.
 Curr Probl Diagn Radiol. 2005 Sep-Oct;34(5):182–95.
- 717 31. van Goor H. Consequences and complications of peritoneal adhesions. Colorectal Dis.
 718 2007 Oct;9 Suppl 2:25–34.
- 32. Falconi M, Pederzoli P. The relevance of gastrointestinal fistulae in clinical practice: a
 review. Gut. 2001 Dec;49 Suppl 4(Suppl 4):iv2–10.
- 33. Gao S, Hendrie HC, Hall KS, Hui S. The relationships between age, sex, and the incidence
 of dementia and Alzheimer disease: a meta-analysis. Arch Gen Psychiatry. 1998
 Sep;55(9):809–15.
- 724 34. Pringsheim T, Jette N, Frolkis A, Steeves TDL. The prevalence of Parkinson's disease: a
 725 systematic review and meta-analysis. Mov Disord. 2014 Nov;29(13):1583–90.
- 35. Momtaz YA, Hamid TA, Ibrahim R. Gastritis May Boost Odds of Dementia. Am J
 Alzheimers Dis Other Demen. 2014 Aug;29(5):452–6.
- 36. Baglietto-Vargas D, Shi J, Yaeger DM, Ager R, LaFerla FM. Diabetes and Alzheimer's
 disease crosstalk. Neurosci Biobehav Rev. 2016 May;64:272–87.

701

- 730 37. Haan MN. Therapy Insight: type 2 diabetes mellitus and the risk of late-onset Alzheimer's disease. Nat Clin Pract Neurol. 2006 Mar;2(3):159-66. 731
 - 38. Xu O, Park Y, Huang X, Hollenbeck A, Blair A, Schatzkin A, et al. Diabetes and risk of Parkinson's disease. Diabetes Care. 2011 Apr;34(4):910-5.
- 39. Doulberis M, Kotronis G, Gialamprinou D, Polyzos SA, Papaefthymiou A, Katsinelos P, 734 et al. Alzheimer's disease and gastrointestinal microbiota; impact of infection 735 involvement. Int J Neurosci. 2021 Mar;131(3):289-301. 736
- 737 40. Li Y, Chen Y, Jiang L, Zhang J, Tong X, Chen D, et al. Intestinal Inflammation and Parkinson's Disease. Aging Dis. 2021 Dec;12(8):2052-68. 738
 - 41. Kim KY, Shin KY, Chang KA. GFAP as a Potential Biomarker for Alzheimer's Disease: A Systematic Review and Meta-Analysis. Cells [Internet]. 2023 May 4:12(9). Available from: http://dx.doi.org/10.3390/cells12091309
 - 42. Szeliga M. Peroxiredoxins in Neurodegenerative Diseases. Antioxidants (Basel) [Internet]. 2020 Nov 30;9(12). Available from: http://dx.doi.org/10.3390/antiox9121203
- 43. Karantzoulis S, Galvin JE. Distinguishing Alzheimer's disease from other major forms of 744 dementia. Expert Rev Neurother. 2011 Nov;11(11):1579-91. 745
- 44. Population Data Science [Internet]. 2019 [cited 2024 Jun 30]. Secure Anonymised 746 Information Linkage Databank (SAIL Databank). Available from: 747 https://popdatasci.swan.ac.uk/centres-of-excellence/sail/ 748
- 45. Kurki MI, Karjalainen J, Palta P, Sipilä TP, Kristiansson K, Donner KM, et al. FinnGen 749 provides genetic insights from a well-phenotyped isolated population. Nature. 2023 750 Jan;613(7944):508-18. 751
 - 46. Kunkle BW, Grenier-Boley B, Sims R, Bis JC, Damotte V, Naj AC, et al. Genetic metaanalysis of diagnosed Alzheimer's disease identifies new risk loci and implicates $A\beta$, tau, immunity and lipid processing. Nat Genet. 2019 Mar;51(3):414-30.
- 47. Nalls MA, Blauwendraat C, Vallerga CL, Heilbron K, Bandres-Ciga S, Chang D, et al. 755 Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: 756 a meta-analysis of genome-wide association studies. Lancet Neurol. 2019 Dec:18(12):1091-102.
 - 48. Collister JA, Liu X, Clifton L. Calculating Polygenic Risk Scores (PRS) in UK Biobank: A Practical Guide for Epidemiologists. Front Genet. 2022 Feb 18;13:818574.
- 49. Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ. Second-generation 761 PLINK: rising to the challenge of larger and richer datasets. Gigascience. 2015 Feb 762 25:4:7. 763
- 50. Lundberg SM, Lee SI. A unified approach to interpreting model predictions. In: 764 Proceedings of the 31st International Conference on Neural Information Processing 765 Systems. Red Hook, NY, USA: Curran Associates Inc.; 2017. p. 4768–77. (NIPS'17). 766
- 767 768

732

733

739

740

741

742 743

752

753

754

757

758

759

760

769

Acknowledgments: 770

771

Funding: 772

- Intramural Research Program of the NIH, National Institute on Aging (NIA), National 773 Institutes of Health, Department of Health and Human Services; project number ZO1 774 AG000534 775
- National Institute of Neurological Disorders and Stroke 776

- 777 Dementia Research Institute [UKDRI supported by the Medical Research Council
 - (UKDRI-3003), Alzheimer's Research UK, and Alzheimer's Society]
 - Welsh Government Joint Programming for Neurodegeneration (MRC: MR/T04604X/1)
- 780 Dementia Platforms UK (MRC: MR/L023784/2)
- 781 MRC Centre for Neuropsychiatric Genetics and Genomics (MR/L010305/1)

783 **Author contributions:**

- 784 Conceptualization: MS, SBC, KSL
- 785 Data acquisition and processing: MS, ES, KSL, HLL, CB, HI, MAN
- 786 Data analyzation: MS, ES, KSL
- 787 Interpretation: All authors contributed
- 788 Writing: All authors contributed

Competing interests:

KSL, HLL, HI, and MAN's participation in this project was part of a competitive contract
awarded to Data Tecnica International LLC by the National Institutes of Health to support
open science research. MAN also currently serves on the scientific advisory board at
Clover Therapeutics and is an advisor and scientific founder at Neuron23 Inc. All other
authors declare they have no competing interests.

Data and materials availability:

Notebooks containing code used in this analysis can be found in the GitHub link here: 798 [https://github.com/NIH-CARD/Gut-Brain-Nexus]. This paper analyzes existing, publicly 799 available data. In addition, complete summary statistics describing these data/processed 300 datasets derived from these data have been deposited in the supplementary materials 301 connected to this publication and are publicly available as of the date of publication. 302 Further, we have developed an interactive resource for the scientific community 303 [https://gut-brain-nexus.streamlit.app/] where researchers can investigate components of 304 the predictive model and can investigate feature effects on a sample level. 305

306 307

778

779

782

789 790

796

797

Figures and Tables:



- 310
- 311

ROC Curve and Balanced Accuracy Comparison for AD



- Fig. 1. Receiver Operating Characteristic Curve and Balanced Accuracy Comparison for AD. Performance evaluation of multi-omics integration models using clinical, genetic, proteomic, and demographic data for AD.
- 315 316

312

313



Fig. 2. Receiver Operating Characteristic Curve and Balanced Accuracy Comparison for PD. Performance evaluation of multi-omics integration models using clinical, genetic, proteomic, and demographic data for PD.

317



- Fig. 3. Feature Importance Plots. (A) Distribution of the top 20 features that had the most substantial effect on the Alzheimer's Disease risk estimates. Each point represents a patient and the amount of effect on model output for each feature depends on its Shapley Additive Explanations (SHAP) value. For example, the effect of the "Demographics/Age_at_recruitment" feature on model output is large and positive (indicating a higher risk) when the patient has high values for "Demographics/Age_at_recruitment" (more red points are on the right side). Similarly, (B) shows the top features for Parkinson's Disease risk estimates.
- 330 331

322

323

324

325

326

327

328



Fig. 4. Study design. The initial phase of our study utilized clinical data sourced from electronic medical records (EMR) alongside genetic and proteomic data obtained from the UK Biobank. Quality control procedures were rigorously applied to clinical and genetic datasets, including filtering for individuals of European ancestry, exclusion of related samples, and extraction of 155 ICD-10 codes representing diagnoses related to digestive, endocrine, nutritional, and metabolic disorders. Proteomic data underwent normalization of protein expression levels as part of quality control measures. The culmination of this phase involved the application of a Cox proportional hazards model, examination of polygenic risk scores, and development of a generalized linear model (GLM). These analyses collectively contributed to the construction of a multi-classification predictive model for Alzheimer's disease (AD) and Parkinson's disease (PD). Phase II of our study entailed validating these findings using data from the Secure Anonymised Information Linkage (SAIL) and FinnGen biobanks.

Prior_IC D10_cod e	Prior_IC D10_cod e_Descri ption	Dataset	Neurode generativ e disease outcome	Hazard Ratio	ci_min	ci_max	P_VAL	P_VAL_ FDR_CO RRECT ED	N_pairs	n
E85	amyloido sis, other/uns pecified	Finngen	AD	3.98	1.20	13.27	2.44E-02	3.65E-02	17	
	amyloido sis	UKB		2.57	1.34	4.94	4.72E-03	2.61E-02	9	182
	diseases of pulp and periapical tissues	Finngen		2.83	1.67	4.82	1.17E-04	2.68E-04	267	
K04	diseases of pulp and periapical tissues	UKB	AD	1.44	1.11	1.87	6.21E-03	3.26E-02	57	3,365
	disorders of lipoprotei n metabolis m and other lipidaemi as	Finngen		5.71	4.76	6.85	1.55E-78	1.46E-76	2,522.00	
E78	disorders of lipoprotei n metabolis m and other lipidaemi as	UKB	AD	1.18	1.09	1.27	1.53E-05	1.34E-04	1090	53,797
E92	disorders of mineral metabolis m	Finngen	AD	6.63	3.51	12.51	5.26E-09	2.10E-08	68.00	
E83	disorders of mineral metabolis m	UKB	AD	1.32	1.08	1.62	7.75E-03	3.88E-02	94	4,435
K29	other gastritis (incl. Duodeniti s)	Finngen	AD	2.40	1.53	3.77	1.35E-04	3.06E-04	416.00	

	gastritis and duodeniti s	UKB		1.20	1.09	1.32	1.45E-04	1.17E-03	523	27,914
K64	haemorrh oids and perianal venous thrombos is	Sail	AD	0.37	0.27	0.51	6.83E-10	8.64E-09	39	11,389
K04	haemorrh oids and perianal venous thrombos is	UKB	AD	0.69	0.59	0.80	6.94E-07	8.10E-06	186	20,162
	Type 1 diabetes, wide definition * (includes E10)	Finngen	AD	2.46	1.63	3.70	1.60E-05	4.22E-05	272	
E10	insulin- dependen t diabetes mellitus	Sail	AD	1.78	1.48	2.13	4.29E-10	5.68E-09	118	6,668
	insulin- dependen t diabetes mellitus	UKB		3.09	2.45	3.90	1.77E-21	1.86E-19	73	1,633
	Type 2 diabetes, wide definition *(include s E11)	Finngen		4.02	3.28	4.92	2.54E-41	8.54E-40	2641	
E11	non- insulin- dependen t diabetes mellitus	Sail	AD	1.27	1.19	1.35	3.77E-14	8.43E-13	1052	72,913
	non- insulin- dependen t diabetes mellitus	UKB		1.47	1.33	1.63	1.19E-14	4.18E-13	476	19,048
K 20	oesophagi tis	Finngen		4.23	2.20	8.13	1.58E-05	4.16E-05	77.00	
K20	oesophagi tis	UKB	AD	1.28	1.10	1.49	1.63E-03	1.00E-02	175	8,660
A04	other	Finngen	AD	2.56	1.22	5.37	1.27E-02	2.01E-02	255.00	

	bacterial intestinal infections									
	other bacterial intestinal infections	Sail		1.37	1.14	1.65	6.29E-04	2.95E-03	117	6,202
	other bacterial intestinal infections	UKB		1.51	1.21	1.89	2.35E-04	1.76E-03	81	3,585
E97	other disorders of fluid, electrolyt e and acid-base balance	Finngen		10.04	7.24	13.93	2.11E-43	8.07E-42	600.00	
E87	other disorders of fluid, electrolyt e and acid-base balance	UKB	AD	1.51	1.34	1.70	6.43E-12	1.35E-10	312	11,313
	other functional intestinal disorders	Finngen		4.37	3.30	5.80	1.02E-24	1.51E-23	886.00	
K59	other functional intestinal disorders	Sail	AD	1.19	1.09	1.29	9.59E-05	5.47E-04	529	29,639
	other functional intestinal disorders	UKB		1.55	1.40	1.73	3.55E-16	1.86E-14	394	15,596
	other noninfecti ve gastroent eritis and colitis	Finngen	AD	2.53	1.40	4.57	2.15E-03	3.98E-03	300.00	
K52	other non- infective gastro- enteritis and colitis	Sail		1.36	1.22	1.50	4.97E-09	5.56E-08	373	23,128
	other non-	UKB	AD	1.37	1.20	1.56	1.75E-06	1.84E-05	250	12,984

	infective gastro- enteritis and colitis									
E14	unspecifi ed diabetes mellitus	Sail		1.49	1.19	1.88	6.05E-04	2.89E-03	73	4,470
E14	unspecifi ed diabetes mellitus	UKB	AD	1.53	1.33	1.75	1.21E-09	1.58E-08	224	8,733
D55	vitamin d deficienc y	Finngen	4.5	13.48	4.76	38.22	9.94E-07	3.16E-06	26.00	
E33	vitamin d deficienc y	UKB	AD	1.95	1.57	2.41	9.97E-10	1.50E-08	87	2,405
E86	volume depletion	Finngen	10	10.65	4.09	27.71	1.24E-06	3.88E-06	161.00	
	volume depletion	UKB	AD	1.78	1.52	2.10	3.26E-12	8.57E-11	153	4,911

348

Table 1. Replicated diagnoses in endocrine, nutritional, metabolic, and digestive 349 systems associated with Alzheimer's Disease (AD) risk. UKB: UK Biobank. 350 SAIL: Secure Anonymised Information Linkage Databank. Prior ICD10 code: 351 initial diagnosis of endocrine, metabolic, digestive system, and nutritional 352 disorders, ci min: Confidence interval minimum, ci max: Confidence interval 353 maximum. P_VAL: p-value. P_VAL_FDR_CORRECTED: p-value after False 354 Discovery Rate corrected. N pairs: Number of individuals identified with both 355 ICD-10 code and neurodegenerative disease outcome. n: Number of individuals 356 identified with ICD-10 code. 357 358

Prior_I CD10_c ode	Prior_I CD10_c ode_Des cription	Dataset	Neurode generati ve disease outcome	Hazard Ratio	ci_min	ci_max	P_VAL	P_VAL_ FDR_C ORREC TED	N_pairs	n
K 57	diverticu lar disease of intestine	Sail	DD	0.75	0.69	0.81	1.74E-11	2.82E-10	555.00	70,198.0 0
K37	diverticu lar disease of intestine	UKB	10	0.69	0.62	0.77	6.24E-11	2.04E-09	354.00	34,801.0 0
K30	functiona l dyspepsi a	Finngen	PD	2.72	1.96	3.76	1.95E-09	1.21E-08	86.00	
	dyspepsi a	UKB	-	1.34	1.13	1.60	8.51E-04	9.26E-03	135.00	8,811.00
	insulin- depende nt diabetes mellitus	Sail		1.59	1.31	1.93	3.36E-06	2.48E-05	101.00	6,668.00
E10	insulin- depende nt diabetes mellitus	UKB	PD	2.65	2.02	3.48	2.44E-12	1.20E-10	53.00	1,608.00
	Type 2 diabetes, wide definitio n*(Inclu des E11)	Finngen		2.04	1.75	2.39	2.06E-19	3.38E-18	421.00	
E11	non- insulin- depende nt diabetes mellitus	UKB	PD	1.21	1.08	1.36	1.36E-03	1.33E-02	330.00	18,815.0 0
K63	other diseases of	Sail	PD	0.84	0.73	0.97	1.51E-02	4.71E-02	205.00	25,877.0 0

	intestine									
	other diseases of intestine	UKB		0.69	0.59	0.80	1.34E-06	2.20E-05	183.00	19,139.0 0
VCC	other disorders of peritoneu m	Sail	PD	0.70	0.53	0.93	1.32E-02	4.21E-02	48.00	7,406.00
Коо	other disorders of peritoneu m	UKB	PD	0.63	0.45	0.87	5.81E-03	4.42E-02	35.00	4,612.00
<i>V5</i> 0	other functiona l intestinal disorders	Finngen	PD	3.19	2.46	4.14	2.02E-18	3.02E-17	178.00	
K59	other functiona l intestinal disorders	UKB	PD	1.56	1.38	1.76	4.81E-13	4.71E-11	301.00	15,431.0 0

360 361 362

363

364

365

366

367

368

369 370 Table 2. Replicated diagnoses in endocrine, nutritional, metabolic, and digestive systems associated with Parkinson's Disease (PD) risk. UKB: UK Biobank. SAIL: Secure Anonymised Information Linkage Databank. Prior_ICD10_code: initial diagnosis of endocrine, metabolic, digestive system, and nutritional disorders. ci_min: Confidence interval minimum. ci_max: Confidence interval maximum. P_VAL: p-value. P_VAL_FDR_CORRECTED: p-value after False Discovery Rate corrected. N_pairs: Number of individuals identified with both ICD-10 code and neurodegenerative disease outcome. n: Number of individuals identified with ICD10_code.

ICD10_c ode	ICD10_c ode_desc ription	ICD10_d iagnosis_ range	Neurode generati ve disease outcome	Hazard Ratio	ci_min	ci_max	P_VAL	N_pairs	n	P_VAL_ FDR_C ORREC TED
A04	Other Bacterial Intestinal Infection s	1-5	AD	2.12	1.28	3.53	3.63E-03	15	434	6.60E-03
A04	Other Bacterial Intestinal Infection s	All	AD	1.51	1.21	1.89	2.35E-04	81	3585	3.35E-04
E10	Insulin- Depende nt Diabetes Mellitus	1-5	AD	3.13	1.85	5.29	2.05E-05	14	325	5.11E-05
E10	Insulin- Depende nt Diabetes Mellitus	5-10	AD	3.08	1.94	4.90	1.96E-06	18	398	9.78E-06
E10	Insulin- Depende nt Diabetes Mellitus	10-15	AD	3.68	2.32	5.85	3.55E-08	18	318	1.60E-07
E10	Insulin- Depende nt Diabetes Mellitus	All	AD	3.09	2.45	3.90	1.77E-21	73	1633	3.55E-20
F11	Non- Insulin- Depende nt Diabetes	5 10		1.22	1.11	1.50	1.015.02	120	5400	4 705 02
	Non- Insulin- Depende nt Diabetes	5-10	AD	1.32	1.11	1.38	1.91E-03	120	3490	4.78E-03
E11 E11	Mellitus Non- Insulin- Depende nt Diabetes Mellitus	All	AD	1.82	1.53	2.17	1.59E-11 1.19E-14	476	4023	2.86E-10 7.96E-14

E14	Unspecifi ed Diabetes Mellitus	5-10	AD	1.79	1.13	2.85	1.36E-02	18	827	2.47E-02
E14	Unspecifi ed Diabetes Mollitus	10.15		2 28	1 76	2.04	4 16E 10	50	1902	2 74E 00
F14	Unspecifi ed Diabetes Mellitus	A11	AD	1 53	1.70	1.75	1.21E-09	224	8733	3.02E-09
E16	Other Disorders Of Pancreati c Internal Secretion	1-5	AD	3.52	2.41	5.15	7.75E-11	221	374	1.55E-09
E16	Other Disorders Of Pancreati c Internal Secretion	5-10	AD	1.87	1.21	2.91	5.12E-03	20	525	1.02E-02
E16	Other Disorders Of Pancreati c Internal Secretion	10-15	AD	2.69	1.34	5.38	5.23E-03	8	180	1.18E-02
E16	Other Disorders Of Pancreati c Internal Secretion	All	AD	2.23	1.75	2.83	5.27E-11	69	1637	1.76E-10
E53	Deficienc y Of Other B Group Vitamins	1-5	AD	2.33	1.66	3.27	9.65E-07	34	700	3.86E-06
E53	Deficienc y Of Other B Group Vitamins	5-10	AD	1.74	1.08	2.80	2.29E-02	17	509	3.81E-02
E53	Deficienc y Of Other B Group Vitamins	All	AD	1.78	1.40	2.27	2.61E-06	68	1939	4.75E-06
E55	Vitamin D Deficienc	1-5	AD	2 35	1 80	3.06	2.47E-10	56	1198	2.47E-09
E55	Vitamin	All	AD	1.95	1.57	2.41	9.97E-10	87	2405	2.85E-09

	D Deficienc y									
E66	Obesity	All	AD	0.85	0.74	0.96	9.29E-03	260	22619	9.29E-03
E78	Disorders Of Lipoprot ein Metaboli sm And Other Lipidaem ias	5-10	AD	1.48	1.29	1.70	3.33E-08	212	8983	3.33E-07
E78	Disorders Of Lipoprot ein Metaboli sm And Other Lipidaem ias	10-15	AD	1.44	1.27	1.63	4.43E-09	288	12012	2.66E-08
F78	Disorders Of Lipoprot ein Metaboli sm And Other Lipidaem ias	All	AD	1 18	1 09	1 27	1 53E-05	1090	53797	2 56E-05
E83	Disorders Of Mineral Metaboli sm	1-5	AD	1.64	1.22	2.21	9.34E-04	45	1522	2.08E-03
E83	Disorders Of Mineral Metaboli sm	All	AD	1.32	1.08	1.62	7.75E-03	94	4435	8.16E-03
E85	Amyloid osis	1-5	AD	3.59	1.61	8.00	1.75E-03	6	81	3.50E-03
E85	Amyloid osis	All	AD	2.57	1.34	4.94	4.72E-03	9	182	5.55E-03
E86	Volume Depletio n	1-5	AD	1.90	1.48	2.44	5.01E-07	63	1678	2.50E-06
E86	Volume Depletio n	5-10	AD	1.89	1.32	2.71	5.28E-04	30	795	1.56E-03
EQ.	Volume Depletio	10.15			1.00	0.41	2 205 02	1-	27.1	0.015.02
E80 E86	n Volume	10-15 All	AD AD	2.09	1.28	3.41 2.10	3.30E-03	16	3/4 4911	9.91E-03
L00	* orunic	All		1./0	1.52	2.10	5.201-12	155	+711	1.050-11

	Depletio n									
E87	Other Disorders Of Fluid, Electroly te And Acid- Base Balance	1-5	AD	1.52	1.27	1.81	3.99E-06	128	4059	1.14E-05
E87	Other Disorders Of Fluid, Electroly te And Acid- Base Balance	5-10	AD	1.72	1.37	2.16	3.78E-06	75	1965	1.51E-05
E87	Other Disorders Of Fluid, Electroly te And Acid- Base Balance	10-15	AD	1.92	1.34	2.75	3.70E-04	30	786	1.33E-03
E87	Other Disorders Of Fluid, Electroly te And Acid- Base Balance	All	AD	1.51	1.34	1.70	6.43E-12	312	11313	2.57E-11
K04	Diseases Of Pulp And Periapica I Tissues	1-5	AD	2.41	1.20	4.82	1.31E-02	8	305	1.87E-02
K04	Diseases Of Pulp And Periapica I Tissues	All	AD	1.44	1.11	1.87	6.21E-03	57	3365	6.90E-03
K20	Oesopha gitis	1-5	AD	1.62	1.16	2.28	4.88E-03	34	1399	8.14E-03
K20	Oesopha gitis	5-10	AD	1.51	1.15	1.99	3.18E-03	52	2290	7.06E-03
K20	Oesopha gitis	All	AD	1.28	1.10	1.49	1.63E-03	175	8660	2.03E-03
K29	Gastritis And Duodenit is	5-10	AD	1.32	1.13	1.55	5.47E-04	160	7742	1.56E-03
K29	Gastritis And	10-15	AD	1.31	1.09	1.57	3.89E-03	120	5837	1.00E-02

	Duodenit is									
K29	Gastritis And Duodenit is	All	AD	1.20	1.09	1.32	1.45E-04	523	27914	2.23E-04
K52	Other Non- Infective Gastro- Enteritis And Colitis	5-10	AD	2.31	1.82	2.93	6.20E-12	69	2086	1.24E-10
K52	Other Non- Infective Gastro- Enteritis And Colitis	10-15	AD	1.36	1.08	1.70	7.92E-03	77	3697	1.43E-02
K52	Other Non- Infective Gastro- Enteritis And Colitis	All	AD	1.37	1.20	1.56	1.75E-06	250	12984	3.50E-06
K59	Other Function al Intestinal Disorders	1-5	AD	1.55	1.30	1.85	1.27E-06	127	4476	4.22E-06
K59	Other Function al Intestinal Disorders	5-10	AD	1.70	1.40	2.07	8.75E-08	105	3464	5.83E-07
K59	Other Function al Intestinal Disorders	10-15	AD	1.41	1.10	1.82	7.32E-03	61	2512	1.43E-02
K59	Other Function al Intestinal Disorders	All	AD	1.55	1.40	1.73	3.55E-16	394	15596	3.55E-15
K64	Haemorr hoids And Perianal Venous Thrombo sis	1-5	AD	0.41	0.29	0.58	2,605-07	3/1	5880	1 73E-06
K64	Haemorr hoids	All	AD	0.41	0.29	0.38	6.94E-07	186	20162	1.54E-06

	And Perianal Venous Thrombo sis									
K66	Other Disorders Of Peritoneu m	1-5	AD	0.49	0.28	0.86	1.28E-02	12	1668	1.87E-02
K66	Other Disorders Of Peritoneu m	All	AD	0.59	0.44	0.81	8.77E-04	41	4636	1.17E-03

374 375 376

377

378

379

380

381

382

383 384 Table 3. Time-Stratified Cox Regression model for Alzheimer's Disease. ICD10_code: initial diagnosis of endocrine, metabolic, digestive system, and nutritional disorders. ICD10_diagnosis_range: Number of years from the initial diagnosis of endocrine, metabolic, digestive system, and nutritional disorders (ICD-10 code) to the occurrence of neurodegenerative disease outcome. ci_min: Confidence interval minimum. ci_max: Confidence interval maximum. P_VAL: p-value. N_pairs: Number of individuals identified with both ICD-10 code and neurodegenerative disease outcome. n: Number of individuals identified with ICD10_code. P_VAL_FDR_CORRECTED: p-value after False Discovery Rate corrected.

ICD10_c ode	ICD10_c ode_desc ription	ICD10_d iagnosis_ range	Neurode generati ve disease outcome	Hazard Ratio	ci min	ci max	P VAL	N pairs	n	P_VAL_ FDR_C ORREC TED
E10	insulin- dependen t diabetes mellitus	5-10	PD	3.08	1.89	5.04	7.15E-06	16	396	4.29E-05
E10	insulin- dependen t diabetes mellitus	10-15	PD	2.53	1.36	4.71	3.39E-03	10	310	1.02E-02
E10	insulin- dependen t diabetes mellitus	All	PD	2.65	2.02	3.48	2.44E-12	53	1608	1.46E-11
	non- insulin- dependen t diabetes									
E11	mellitus non- insulin- dependen t diabetes	5-10	PD	1.41	1.16	1.70	4.19E-04	112	5480	8.38E-04
EII	non- insulin- dependen t diabetes	10-15	PD	1.40	1.13	1.74	2.03E-03	86	3976	8.10E-03
E11 E14	unspecifi ed diabetes mellitus	All 1-5	PD PD	1.21	1.08	3.22	1.36E-03	15	623	1.63E-03
E14	unspecifi ed diabetes mellitus	5-10	PD	2.66	1.76	4.01	3.04E-06	23	832	3.65E-05
E14	unspecifi ed diabetes mellitus	10-15	PD	1.94	1.45	2.60	8.17E-06	46	1790	9.80E-05
E14	unspecifi ed diabetes mellitus	All	PD	1.61	1.39	1.86	1.81E-10	197	8658	5.44E-10
E16	other disorders of pancreati c internal	1-5	PD	1.89	1.04	3.42	3.54E-02	11	358	4.73E-02

	secretion									
E16	other disorders of pancreati c internal secretion	5-10	PD	1.94	1.17	3.22	1.06E-02	15	520	1.81E-02
E16	other disorders of pancreati c internal secretion	All	PD	1.84	1.36	2.47	6.76E-05	44	1602	1.16E-04
E53	deficienc y of other b group vitamins	1-5	PD	2.04	1.34	3.10	8.81E-04	22	688	2.64E-03
E53	deficienc y of other b group vitamins	All	PD	1.72	1.30	2.29	1.88E-04	48	1907	2.81E-04
E66	obesity	1-5	PD	0.63	0.47	0.83	1.45E-03	47	6561	2.95E-03
E66	obesity	All	PD	0.82	0.71	0.94	5.86E-03	211	22453	5.86E-03
K30	dyspepsi a	5-10	PD	1.84	1.39	2.44	1.90E-05	50	2480	7.61E-05
K30	dyspepsi a	All	PD	1.34	1.13	1.60	8.51E-04	135	8811	1.13E-03
K57	diverticul ar disease of intestine	1-5	PD	0.60	0.48	0.75	8.54E-06	77	10132	5.12E-05
V 57	diverticul ar disease of	5 10	PD	0.69	0.56	0.83	1 10E 04	104	10967	2 95E 04
K37	diverticul ar disease of	5-10	PD	0.08	0.30	0.83	1.19E-04	104	10807	2.63E-04
K57	intestine	All	PD	0.69	0.62	0.77	6.24E-11	354	34801	2.50E-10
K59	other functiona l intestinal disorders	1-5	PD	1.51	1.23	1.86	8.27E-05	94	4443	3.31E-04
	other functiona l									
K59	intestinal disorders	5-10	PD	1.62	1.29	2.03	3.70E-05	76	3435	1.11E-04
K59	other functiona	10-15	PD	1.61	1.22	2.12	7.90E-04	51	2502	4.74E-03

	l intestinal disorders									
K 59	other functiona l intestinal disorders	Δ11	PD	1 56	1 38	1 76	4 81F-13	301	15431	5 77E-12
	other diseases of			1.50	1.50	1.70	4.01L-13	501	13+31	5.1712-12
K63	intestine	1-5	PD	0.61	0.45	0.83	1.47E-03	42	5726	2.95E-03
K63	other diseases of intestine	5-10	PD	0.74	0.57	0.95	1.67E-02	62	6182	2.23E-02
N/CO	other diseases of	10.15	DD	0.70	0.50	0.04	1.045.00		4000	4.405.00
K63	other diseases of	10-15	PD	0.70	0.52	0.94	1.84E-02	44	4008	4.40E-02
<u>K63</u>	haemorrh oids and perianal venous thrombos	All		0.69	0.59	0.80	1.34E-06	183	19139	2.69E-06
K64	1S haemorrh oids and perianal venous thrombos	5.10	PD	0.39	0.27	0.57	1.01E-06	27	5873	1.22E-05
K64	haemorrh oids and perianal venous thrombos	5-10 All	PD	0.00	0.47	0.92	1.55E-02	136	20006	8.69E-09
	other disorders of peritoneu	1.5		0.39	0.50	0.71	5.02E-07	- 130	20000	0.012.03
K66	m other disorders of peritoneu	A 11	PD	0.34	0.16	0.72	4.79E-03	25	1663	5.86E 02
1200	111	All	עו	0.05	0.43	0.07	0.010-03	33	4012	2.000-02

387 388

 Table 4. Time-Stratified Cox Regression model for Parkinson's Disease. ICD10_code:

 initial diagnosis of endocrine, metabolic, digestive system, and nutritional

390	disorders. ICD10_diagnosis_range: Number of years from the initial diagnosis of
391	endocrine, metabolic, digestive system, and nutritional disorders (ICD-10 code) to
392	the occurrence of neurodegenerative disease outcome. ci_min: Confidence interval
393	minimum. ci_max: Confidence interval maximum. P_VAL: p-value. N_pairs:
394	Number of individuals identified with both ICD-10 code and neurodegenerative
395	disease outcome. n: Number of individuals identified with ICD10_code.
396	P_VAL_FDR_CORRECTED: p-value after False Discovery Rate corrected.
397	

Olink_ marker _being_ compar ed	Olink_ marker _definit ion	ICD10_ Code	ICD10_ Code_d efinitio n	Averag e Olink_ marker level in individ uals diagnos ed with only AD (AD)	Averag e Olink_ marker level in individ uals diagnos ed with both AD and ICD-10 code (AD + ICD-10)	T- Statistic (AD + ICD-10 vs. AD)	Degrees of Freedo m	AD_size	AD_IC D10_siz e	P-Value	P_VAL _FDR_ CORR ECTED
gfap	Glial fibrillar y acidic protein	p130708	Non- Insulin- Depend ent Diabetes Mellitus	0.735	0.45	-4.05	544	437	109	8.20E- 05	1.45E- 03
gfap	Glial fibrillar y acidic protein	p131598	Gastritis And Duodeni tis	0.722	0.50	-3.46	544	439	107	6.74E- 04	8.42E- 03
gfap	Glial fibrillar y acidic protein	p130714	Unspeci fied Diabetes Mellitus	0.713	0.42	-3.31	544	482	64	1.43E- 03	1.47E- 02
adoro1	Adhesio n G- protein coupled receptor G1	n130792	Obesity	0 485	1 39	4 80	556	497	61	9.17E- 06	2.29E- 04
adorol	Adhesio n G- protein coupled receptor G1	p130714	Unspeci fied Diabetes Mellitus	0.455	1.52	6.12	556	491	67	4.08E- 08	1.75E- 06
adgrg1	Adhesio n G- protein coupled receptor G1	p130708	Non- Insulin- Depend ent Diabetes Mellitus	0.393	1.35	7.21	556	447	111	3.60E- 11	5.40E- 09
calb1	Calbindi n	p131582	Oesopha gitis	0.162	0.41	2.96	556	520	38	5.05E- 03	4.10E- 02
calb1	Calbindi n	p130718	Other Disorder s Of Pancreat ic	0.167	0.38	3.07	556	527	31	4.06E- 03	3.48E- 02

			Internal Secretio n								
calb1	Calbindi n	p130824	Amyloi dosis	0.177	0.55	12.23	556	556	2	1.86E- 03	1.80E- 02
dcn	Decorin	p130828	Other Disorder s Of Fluid, Electrol yte And Acid- Base Balance	0.118	0.20	2.86	552	418	136	4.68E- 03	3.90E- 02
			Volume Depletio							2.71E-	2.54E-
dcn	Decorin	p130826	n Volumo	0.119	0.21	3.05	552	442	112	03	02
ren	Renin	p130826	Depletio n	0.340	0.67	2.77	559	445	116	6.23E- 03	4.67E- 02
ren	Renin	p130770	Deficien cy Of Other B Group Vitamin s	0.367	1.01	3.41	559	524	37	1.46E- 03	1.47E- 02
ren	Renin	p130792	Obesity	0.349	0.89	3.71	559	499	62	3.89E- 04	5.07E- 03
ren	Renin	p131640	Other Functio nal Intestina 1 Disorder s	0.310	0.70	3.76	559	420	141	2.17E- 04	3.25E- 03
ren	Renin	p130706	Insulin- Depend ent Diabetes Mellitus	0.369	1.62	3.78	559	543	18	1.43E- 03	1.47E- 02
ren	Renin	p130718	Other Disorder s Of Pancreat ic Internal Secretio n	0.349	1.46	4.30	559	531	30	1.60E- 04	2.67E- 03
		-	Unspeci								
ren	Renin	p130714	Diabetes Mellitus	0.293	1.25	5.73	559	493	68	1.86E- 07	6.97E- 06
ren	Renin	p130708	Non- Insulin- Depend ent	0.253	1.02	5.97	559	447	114	1.74E- 08	8.71E- 07

			Diabetes Mellitus								
ren	Renin	p130814	Disorder s Of Lipoprot ein Metabol ism And Other Lipidae mias	0.161	0.69	6.02	559	296	265	3.38E- 09	2.54E- 07
odf15	Growth/ different iation factor 15	n131582	Oesopha gitis	0 415	0.82	3 12	568	530	40	3.32E- 03	3.01E- 02
gdf15	Growth/ different iation factor 15	p130826	Volume Depletio n	0.399	0.62	3.28	568	453	117	1.26E- 03	1.45E- 02
gdf15	Growth/ different iation factor 15	p130820	Disorder s Of Mineral Metabol ism	0.418	0.83	3.89	568	535	35	3.85E- 04	5.07E- 03
gdf15	Growth/ different iation factor 15	p130828	Other Disorder s Of Fluid, Electrol yte And Acid- Base Balance	0.382	0.63	4.26	568	431	139	3.03E- 05	6.49E- 04
gdf15	Growth/ different iation factor 15	p130706	Insulin- Depend ent Diabetes Mellitus	0.418	1.22	4.47	568	552	18	3.12E- 04	4.46E- 03
gdf15	Growth/ different iation factor 15	p130792	Obesity	0.400	0.80	4.48	568	508	62	2.76E- 05	6.36E- 04
gdf15	Growth/ different iation factor 15	p130814	Disorder s Of Lipoprot ein Metabol ism And Other Lipidae mias	0.338	0.56	4.68	568	302	268	3.64E- 06	1.21E- 04
gdf15	Growth/ different	p130718	Other Disorder	0.409	1.06	4.82	568	540	30	3.68E- 05	7.36E- 04

	iation factor 15		s Of Pancreat ic Internal Secretio n								
gdf15	Growth/ different iation factor 15	p130708	Non- Insulin- Depend ent Diabetes Mellitus	0.336	0.87	7.47	568	455	115	7.97E- 12	2.39E- 09
gdf15	Growth/ different iation factor 15	p130714	Unspeci fied Diabetes Mellitus	0.359	1.06	7.51	568	501	69	9.20E- 11	9.20E- 09
igf2r	Cation- indepen dent mannos e-6- phospha te receptor	p130714	Unspeci fied Diabetes Mellitus	0.065	0.17	3.39	558	492	68	1.04E- 03	1.24E- 02
	Cation- indepen dent mannos e-6- phospha te	120702		0.064	0.10	2.04	550	100	(2)	1.74E-	2.74E-
igf2r	Cation- indepen dent mannos e-6- phospha te	p130792	Non- Insulin- Depend ent Diabetes Mellitus	0.064	0.19	4.75	558	498	114	4.15E- 06	1.24E- 04
illr1	Interleu kin-1 receptor type 1	p130706	Insulin- Depend ent Diabetes Mellitus	0.053	0.30	3.75	556	540	114	1.47E- 03	1.47E- 02
il1r1	Interleu kin-1 receptor type 1	p130714	Unspeci fied Diabetes Mellitus	0.039	0.20	4.77	556	491	67	7.80E- 06	2.13E- 04
il1r1	Interleu kin-1 receptor type 1	p130708	Non- Insulin- Depend ent Diabetes Mellitus	0.027	0.18	5.99	556	444	114	1.17E- 08	7.01E- 07

il1rl1	Interleu kin-1 receptor -like 1	p130708	Non- Insulin- Depend ent Diabetes Mellitus	0.109	0.26	2.80	566	454	114	5.67E- 03	4.48E- 02
il1rl1	Interleu kin-1 receptor -like 1	p130714	Unspeci fied Diabetes Mellitus	0.115	0.31	2.81	566	500	68	6.14E- 03	4.67E- 02
il1rl1	Interleu kin-1 receptor -like 1	p130718	Other Disorder s Of Pancreat ic Internal Secretio n	0.121	0.46	3.12	566	538	30	3.82E- 03	3.37E- 02
ltbp2	Latent- transfor ming growth factor beta- binding protein 2	p130828	Other Disorder s Of Fluid, Electrol yte And Acid- Base Balance	0.243	0.39	4.08	568	431	139	6.02E- 05	1.13E- 03

)00

901

)02

)02

Table 5. Proteomic biomarker comparison in isolated Alzheimer's Disease (AD) casesvs. cases with digestive, endocrine, metabolic, and nutritional conditions.P_VAL_FDR_CORRECTED: p-value after False Discovery Rate (FDR)corrected.

€04 905

Olink_ marker _being_ compar ed	Olink_ marker _definit ion	ICD10_ Code	ICD10_ Code_d efinitio n	Averag e Olink_ marker level in individ uals diagnos ed with only PD (PD)	Averag e Olink_ marker level in individ uals diagnos ed with both PD and ICD-10 code (PD + ICD-10)	T- Statistic (PD + ICD-10 vs. PD)	Degrees of Freedo m	AD_size	AD_IC D10_siz e	P-Value	P_VAL _FDR_ CORR ECTED
Collage nase 3	mmp13	p131600	dyspepsi a	0.04	0.23	3.28	603	569	36	2.08E- 03	4.97E- 02
Peroxire doxin-1	prdx 1	p130706	insulin- depende nt diabetes mellitus	0.22	-0.43	-3.60	603	589	16	2.13E- 03	4.97E- 02
CD276 antigen	cd276	p130708	non- insulin- depende nt diabetes mellitus	0.08	0.23	3.38	623	523	102	9.29E- 04	4.33E- 02
CD276 antigen	cd276	p130714	unspecif ied diabetes mellitus	0.09	0.33	3.40	623	569	56	1.20E- 03	4.33E- 02
CD276 antigen	cd276	p130706	insulin- depende nt diabetes mellitus	0.09	0.70	4.38	623	609	16	5.06E- 04	3.64E- 02
Interleu kin-1 receptor -like 1	il1rl1	p130714	unspecif ied diabetes mellitus	0.13	0.39	3.92	631	575	58	1.99E- 04	2.87E- 02
Neural cell adhesio n molecul e 1	ncam1	p130792	obesity	0.13	-0.03	-3.12	628	550	80	2.42E- 03	4.97E- 02

908 909

)10

∂11

∂12

corrected.

Table 6. Proteomic biomarker comparison in isolated Parkinson's Disease (PD) cases

P_VAL_FDR_CORRECTED: p-value after False Discovery Rate (FDR)

vs. cases with digestive, endocrine, metabolic, and nutritional conditions.